Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Fractyl Health Inc.
Headquarters: Lexington, MA, United States of America
Website: https://www.fractyl.com/
Year Founded: 2010
Status: Public
Industry Sector: HealthTechnology
CEO: Harith Rajagopalan, MD, PhD
Number Of Employees: 107
Enterprise Value: $95,472,229
PE Ratio: -0.78
Exchange/Ticker 1: NASDAQ:GUTS
Exchange/Ticker 2: N/A
Latest Market Cap: $56,747,400
BioCentury | Jul 3, 2024
Discovery & Translation
Science Spotlight: Epigenetic editor for brain prion silencing, Mopac’s oral biologics and more
BioCentury’s roundup of translational innovations
BioCentury | May 23, 2024
Management Tracks
Elias Zerhouni to chair Boston Pharmaceuticals
Plus: SystImmune names Jonathan Cheng CMO, and updates from CRISPR,
BioCentury | Apr 4, 2024
Management Tracks
Upstream names new CEO, CFO and COO
Plus: Acadia hires Elizabeth Thompson as head of R&D, and updates from Insitro, Fractyl, Adarx and more
BioCentury | Feb 13, 2024
Product Development
ADCs, psychedelics & biotech IPOs: BioCentury’s latest podcast
Plus: Gilead’s $4.3B takeout of CymaBay
BioCentury | Feb 10, 2024
Finance
Year’s start mostly strong for biotech IPOs
Four of six companies to go public on U.S. exchanges post positive aftermarket moves
BioCentury | Feb 6, 2024
Product Development
BMS’s patent cliff challenge, and Congress targets China biotech: BioCentury’s latest podcast
Plus: IPO sentiment and the innovation behind 2023’s series A companies
BioCentury | Feb 2, 2024
Finance
Public equity roundup: Alto, Fractyl price IPOs, Vaxcyte raises $750M
Plus: Kyverna lining up a listing next week, and PIPEs for Tectonic, Tyra and Arcus
BioCentury | Jan 30, 2024
Finance
Biotech IPOs & momentum in the IL-18 field: BioCentury’s latest podcast
Plus: the schizophrenia pipeline and what’s next for Singapore biotech
BioCentury | Jan 12, 2024
Finance
The year of biotech’s recovery
Public Markets Preview: Investors say biotech outperformance in 2024 will hinge on the interest rate environment
BioCentury | Dec 16, 2023
Finance
Dec. 15 Quick Takes: Pfizer, Nona in ADC deal
Plus: FDA approves Padcev/Keytruda for 1L advanced urothelial cancer, obesity play Fractyl files for IPO and updates from Merck, Syndax, AC Immune, BMS
Items per page:
1 - 10 of 12